Cargando…

IgA Plasma Cell Leukemia

Plasma cell leukemia (PCL) is a rare entity. There are two presentations of PCL, primary or secondary. The primary or de novo form of PCL presents with an acute and rapidly progressive leukemic phase. This form occurs when the patient has no pre-existing multiple myeloma (MM). The secondary form is...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Tejinder, Premalata, CS, Sajeevan, KV, Jain, Ankit, Batra, Ullas, Saini, KS, Satheesh, CT, Babu, K Govind, Lokanatha, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167960/
https://www.ncbi.nlm.nih.gov/pubmed/21938244
http://dx.doi.org/10.4103/0974-2727.44415
_version_ 1782211308444188672
author Singh, Tejinder
Premalata, CS
Sajeevan, KV
Jain, Ankit
Batra, Ullas
Saini, KS
Satheesh, CT
Babu, K Govind
Lokanatha, D
author_facet Singh, Tejinder
Premalata, CS
Sajeevan, KV
Jain, Ankit
Batra, Ullas
Saini, KS
Satheesh, CT
Babu, K Govind
Lokanatha, D
author_sort Singh, Tejinder
collection PubMed
description Plasma cell leukemia (PCL) is a rare entity. There are two presentations of PCL, primary or secondary. The primary or de novo form of PCL presents with an acute and rapidly progressive leukemic phase. This form occurs when the patient has no pre-existing multiple myeloma (MM). The secondary form is the most advanced form of MM. The PCL is a rare disorder representing 1–2% of the diagnosed cases of MM. Median age at presentation is usually above 50 years. The monoclonal protein in patients with PCL may be IgG (50%), IgA (15%), or in rare cases IgD or IgE (6%). We report a case of IgA primary PCL that is very rare. Patient was started on combination therapy with vincristine, adriamycin, and dexamethasone. There was poor response and patient died three months after diagnosis.
format Online
Article
Text
id pubmed-3167960
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31679602011-09-21 IgA Plasma Cell Leukemia Singh, Tejinder Premalata, CS Sajeevan, KV Jain, Ankit Batra, Ullas Saini, KS Satheesh, CT Babu, K Govind Lokanatha, D J Lab Physicians Case Report Plasma cell leukemia (PCL) is a rare entity. There are two presentations of PCL, primary or secondary. The primary or de novo form of PCL presents with an acute and rapidly progressive leukemic phase. This form occurs when the patient has no pre-existing multiple myeloma (MM). The secondary form is the most advanced form of MM. The PCL is a rare disorder representing 1–2% of the diagnosed cases of MM. Median age at presentation is usually above 50 years. The monoclonal protein in patients with PCL may be IgG (50%), IgA (15%), or in rare cases IgD or IgE (6%). We report a case of IgA primary PCL that is very rare. Patient was started on combination therapy with vincristine, adriamycin, and dexamethasone. There was poor response and patient died three months after diagnosis. Medknow Publications 2009 /pmc/articles/PMC3167960/ /pubmed/21938244 http://dx.doi.org/10.4103/0974-2727.44415 Text en © Journal of Laboratory Physicians http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Singh, Tejinder
Premalata, CS
Sajeevan, KV
Jain, Ankit
Batra, Ullas
Saini, KS
Satheesh, CT
Babu, K Govind
Lokanatha, D
IgA Plasma Cell Leukemia
title IgA Plasma Cell Leukemia
title_full IgA Plasma Cell Leukemia
title_fullStr IgA Plasma Cell Leukemia
title_full_unstemmed IgA Plasma Cell Leukemia
title_short IgA Plasma Cell Leukemia
title_sort iga plasma cell leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167960/
https://www.ncbi.nlm.nih.gov/pubmed/21938244
http://dx.doi.org/10.4103/0974-2727.44415
work_keys_str_mv AT singhtejinder igaplasmacellleukemia
AT premalatacs igaplasmacellleukemia
AT sajeevankv igaplasmacellleukemia
AT jainankit igaplasmacellleukemia
AT batraullas igaplasmacellleukemia
AT sainiks igaplasmacellleukemia
AT satheeshct igaplasmacellleukemia
AT babukgovind igaplasmacellleukemia
AT lokanathad igaplasmacellleukemia